• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.基于参考组织的18F-AV-1451用于tau成像的动力学评估
J Nucl Med. 2017 Feb;58(2):332-338. doi: 10.2967/jnumed.116.175273. Epub 2016 Sep 1.
2
Kinetic Modeling of the Tau PET Tracer F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects.在健康志愿者和阿尔茨海默病患者中tau PET 示踪剂 F-AV-1451 的动力学建模。
J Nucl Med. 2017 Jul;58(7):1124-1131. doi: 10.2967/jnumed.116.182881. Epub 2016 Dec 1.
3
Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.(S)-¹⁸F-THK5117 作为评估 Tau 病理学的 PET 示踪剂的示踪动力学分析。
J Nucl Med. 2016 Apr;57(4):574-81. doi: 10.2967/jnumed.115.158519. Epub 2016 Jan 21.
4
Pharmacokinetic Evaluation of the Tau PET Radiotracer F-T807 (F-AV-1451) in Human Subjects.Tau正电子发射断层显像剂F-T807(F-AV-1451)在人体受试者中的药代动力学评估
J Nucl Med. 2017 Mar;58(3):484-491. doi: 10.2967/jnumed.115.170910. Epub 2016 Sep 22.
5
In Vivo Comparison of Tau Radioligands F-THK-5351 and F-THK-5317.Tau放射性配体F-THK-5351和F-THK-5317的体内比较
J Nucl Med. 2017 Jun;58(6):996-1002. doi: 10.2967/jnumed.116.182980. Epub 2016 Nov 10.
6
Modeling Strategies for Quantification of In Vivo F-AV-1451 Binding in Patients with Tau Pathology.tau病理患者体内F-AV-1451结合定量的建模策略
J Nucl Med. 2017 Apr;58(4):623-631. doi: 10.2967/jnumed.116.174508. Epub 2016 Oct 20.
7
Spatially constrained kinetic modeling with dual reference tissues improves F-flortaucipir PET in studies of Alzheimer disease.在阿尔茨海默病研究中,采用双参考组织的空间约束动力学建模可改善F-氟代脱氧吡咯葡糖正电子发射断层显像(F-flortaucipir PET)。
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3172-3186. doi: 10.1007/s00259-020-05134-w. Epub 2021 Feb 18.
8
Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease.Tau正电子发射断层显像剂18F-AV-1451(T807)在认知功能正常、轻度认知障碍和阿尔茨海默病患者中的动力学研究
J Nucl Med. 2016 Oct;57(10):1535-1542. doi: 10.2967/jnumed.115.170027. Epub 2016 May 5.
9
Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of F-PI-2620 PET for the Assessment of Tau Deposits in the Human Brain.评估 F-PI-2620 PET 用于评估人类大脑 Tau 沉积物的剂量学、定量方法和复测变异性。
J Nucl Med. 2020 Jun;61(6):920-927. doi: 10.2967/jnumed.119.236240. Epub 2019 Nov 11.
10
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).使用放射性配体 18F-AV-45(florbetapir [校正] F 18)对阿尔茨海默病中的淀粉样蛋白沉积进行体内成像。
J Nucl Med. 2010 Jun;51(6):913-20. doi: 10.2967/jnumed.109.069088.

引用本文的文献

1
Plasma p-tau217 predicting brain-wide tau accumulation in preclinical AD.血浆p-tau217可预测临床前阿尔茨海默病患者全脑tau蛋白积累。
J Prev Alzheimers Dis. 2025 Jun 20:100252. doi: 10.1016/j.tjpad.2025.100252.
2
Tau Imaging: Use and Implementation in New Diagnostic and Therapeutic Paradigms for Alzheimer's Disease.tau蛋白成像:在阿尔茨海默病新诊断和治疗模式中的应用与实施
Geriatrics (Basel). 2025 Feb 14;10(1):27. doi: 10.3390/geriatrics10010027.
3
Cognitive aging outcomes are related to both tau pathology and maintenance of cingulate cortex structure.认知衰老结果与tau病理和扣带回皮质结构的维持均有关。
Alzheimers Dement. 2025 Feb;21(2):e14515. doi: 10.1002/alz.14515. Epub 2025 Jan 14.
4
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials.阿尔茨海默病神经影像学计划概述及未来临床试验
Alzheimers Dement. 2025 Jan;21(1):e14321. doi: 10.1002/alz.14321. Epub 2024 Dec 22.
5
Implementation and Assessment of Tau Thresholds in Non-Demented Individuals as Predictors of Cognitive Decline in Tau Imaging Studies.在tau 影像学研究中,非痴呆个体 tau 阈值的实施和评估作为认知下降的预测因子。
J Alzheimers Dis. 2024;100(s1):S75-S92. doi: 10.3233/JAD-240543.
6
Tau accumulation and atrophy predict amyloid independent cognitive decline in aging.tau 蛋白积累和萎缩可预测衰老中与淀粉样蛋白无关的认知能力下降。
Alzheimers Dement. 2024 Apr;20(4):2526-2537. doi: 10.1002/alz.13654. Epub 2024 Feb 9.
7
A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.一篇关于用于tau神经原纤维缠结正电子发射断层扫描成像的氟替卡匹文献综述。
Brain Commun. 2023 Nov 16;6(1):fcad305. doi: 10.1093/braincomms/fcad305. eCollection 2024.
8
Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge.TREM2 p.R47H 携带者和轻度认知障碍患者的小胶质细胞激活、tau 和淀粉样蛋白沉积:流感疫苗免疫挑战的多模态/多示踪剂 PET/MRI 成像研究。
J Neuroinflammation. 2023 Nov 21;20(1):272. doi: 10.1186/s12974-023-02945-0.
9
[F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration.[F]PI-2620 在疑似阿尔茨海默病和额颞叶变性患者中的结合模式。
J Nucl Med. 2023 Dec 1;64(12):1980-1989. doi: 10.2967/jnumed.123.265856.
10
NODDI-derived measures of microstructural integrity in medial temporal lobe white matter pathways are associated with Alzheimer's disease pathology and cognitive outcomes.基于NODDI得出的内侧颞叶白质通路微观结构完整性测量指标与阿尔茨海默病病理学及认知结果相关。
bioRxiv. 2023 Oct 16:2023.10.11.561946. doi: 10.1101/2023.10.11.561946.

本文引用的文献

1
Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease.Tau正电子发射断层显像剂18F-AV-1451(T807)在认知功能正常、轻度认知障碍和阿尔茨海默病患者中的动力学研究
J Nucl Med. 2016 Oct;57(10):1535-1542. doi: 10.2967/jnumed.115.170027. Epub 2016 May 5.
2
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.18F-THK5351:一种用于阿尔茨海默病神经纤维病理成像的新型正电子发射断层显像剂。
J Nucl Med. 2016 Feb;57(2):208-14. doi: 10.2967/jnumed.115.164848. Epub 2015 Nov 5.
3
Tau positron emission tomographic imaging in aging and early Alzheimer disease.衰老和早期阿尔茨海默病中的tau正电子发射断层成像
Ann Neurol. 2016 Jan;79(1):110-9. doi: 10.1002/ana.24546. Epub 2015 Dec 15.
4
Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue.在尸检脑组织上验证新型tau正电子发射断层显像示踪剂[F-18]-AV-1451(T807)
Ann Neurol. 2015 Nov;78(5):787-800. doi: 10.1002/ana.24517. Epub 2015 Sep 25.
5
Tau imaging: early progress and future directions.tau 成像:早期进展与未来方向。
Lancet Neurol. 2015 Jan;14(1):114-24. doi: 10.1016/S1474-4422(14)70252-2.
6
The simplified reference tissue model: model assumption violations and their impact on binding potential.简化参考组织模型:模型假设违背及其对结合潜能的影响
J Cereb Blood Flow Metab. 2015 Feb;35(2):304-11. doi: 10.1038/jcbfm.2014.202. Epub 2014 Nov 26.
7
Primary age-related tauopathy (PART): a common pathology associated with human aging.原发性年龄相关性tau蛋白病(PART):一种与人类衰老相关的常见病理状态。
Acta Neuropathol. 2014 Dec;128(6):755-66. doi: 10.1007/s00401-014-1349-0. Epub 2014 Oct 28.
8
Tau PET imaging in Alzheimer's disease.阿尔茨海默病中的 Tau 蛋白正电子发射断层显像
Curr Neurol Neurosci Rep. 2014 Nov;14(11):500. doi: 10.1007/s11910-014-0500-6.
9
Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.使用 18F-THK5105 PET 进行阿尔茨海默病神经纤维缠结的无创评估。
Brain. 2014 Jun;137(Pt 6):1762-71. doi: 10.1093/brain/awu064. Epub 2014 Mar 27.
10
Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies.评估 THK523 对阿尔茨海默病和非阿尔茨海默病 tau 病中 tau 沉积物的选择性。
Alzheimers Res Ther. 2014 Feb 26;6(1):11. doi: 10.1186/alzrt240. eCollection 2014.

基于参考组织的18F-AV-1451用于tau成像的动力学评估

Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.

作者信息

Baker Suzanne L, Lockhart Samuel N, Price Julie C, He Mark, Huesman Ronald H, Schonhaut Daniel, Faria Jamie, Rabinovici Gil, Jagust William J

机构信息

Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Lab, Berkeley, California

Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California.

出版信息

J Nucl Med. 2017 Feb;58(2):332-338. doi: 10.2967/jnumed.116.175273. Epub 2016 Sep 1.

DOI:10.2967/jnumed.116.175273
PMID:27587706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5288744/
Abstract

UNLABELLED

The goal of this paper was to evaluate the in vivo kinetics of the novel tau-specific PET radioligand F-AV-1451 in cognitively healthy control (HC) and Alzheimer disease (AD) subjects, using reference region analyses.

METHODS

F-AV-1451 PET imaging was performed on 43 subjects (5 young HCs, 23 older HCs, and 15 AD subjects). Data were collected from 0 to 150 min after injection, with a break from 100 to 120 min. T1-weighted MR images were segmented using FreeSurfer to create 14 bilateral regions of interest (ROIs). In all analyses, cerebellar gray matter was used as the reference region. Nondisplaceable binding potentials (BPs) were calculated using the simplified reference tissue model (SRTM) and SRTM2; the Logan graphical analysis distribution volume ratio (DVR) was calculated for 30-150 min (DVR30-150). These measurements were compared with each other and used as reference standards for defining an appropriate 20-min window for the SUV ratio (SUVR). Pearson correlations were used to compare the reference standards to 20-min SUVRs (start times varied from 30 to 130 min), for all values, for ROIs with low F-AV-1451 binding (lROIs, mean of BP + 1 and DVR30-150 < 1.5), and for ROIs with high F-AV-1451 binding (hROIs, mean of BP + 1 and DVR30-150 > 1.5).

RESULTS

SRTM2 BP + 1 and DVR30-150 were in good agreement. Both were in agreement with SRTM BP + 1 for lROIs but were greater than SRTM BP + 1 for hROIs, resulting in a nonlinear relationship. hROI SUVRs increased from 80-100 to 120-140 min by 0.24 ± 0.15. The SUVR time interval resulting in the highest correlation and slope closest to 1 relative to the reference standards for all values was 120-140 min for hROIs, 60-80 min for lROIs, and 80-100 min for lROIs and hROIs. There was minimal difference between methods when statistical significance between ADs and HCs was calculated.

CONCLUSION

Despite later time periods providing better agreement between reference standards and SUVRs for hROIs, a good compromise for studying lROIs and hROIs is SUVR80-100. The lack of SUVR plateau for hROIs highlights the importance of precise acquisition time for longitudinal assessment.

摘要

未标注

本文的目的是使用参考区域分析方法,评估新型tau特异性正电子发射断层显像(PET)放射性配体F-AV-1451在认知健康对照(HC)和阿尔茨海默病(AD)受试者体内的动力学情况。

方法

对43名受试者(5名年轻HC、23名年长HC和15名AD受试者)进行了F-AV-1451 PET成像。在注射后0至150分钟收集数据,中间在100至120分钟有中断。使用FreeSurfer对T1加权磁共振图像进行分割,以创建14个双侧感兴趣区域(ROI)。在所有分析中,小脑灰质用作参考区域。使用简化参考组织模型(SRTM)和SRTM2计算不可置换结合电位(BP);计算30至150分钟的洛根图形分析分布容积比(DVR)(DVR30-150)。将这些测量值相互比较,并用作定义SUV比(SUVR)合适20分钟窗口的参考标准。使用Pearson相关性将参考标准与20分钟SUVR(开始时间从30到130分钟不等)进行比较,针对所有值、F-AV-1451结合低的ROI(低结合ROI,BP + 1和DVR30-150的平均值 < 1.5)以及F-AV-1451结合高的ROI(高结合ROI,BP + 1和DVR30-150的平均值 > 1.5)。

结果

SRTM2 BP + 1和DVR30-150高度一致。对于低结合ROI,两者均与SRTM BP + 1一致,但对于高结合ROI,它们大于SRTM BP + 1,导致非线性关系。高结合ROI的SUVR在80 - 100至120 - 140分钟增加了0.24 ± 0.15。相对于所有值的参考标准,导致最高相关性且斜率最接近1的SUVR时间间隔,对于高结合ROI为120 - 140分钟,对于低结合ROI为60 - 80分钟,对于低结合ROI和高结合ROI均为80 - 100分钟。在计算AD和HC之间的统计学显著性时,各方法之间差异极小。

结论

尽管较晚的时间段在参考标准和高结合ROI的SUVR之间提供了更好的一致性,但对于研究低结合ROI和高结合ROI而言,SUVR80-100是一个不错的折衷选择。高结合ROI缺乏SUVR平台期突出了精确采集时间对于纵向评估的重要性。